تداخلات إكسيميستان

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1 IES 027 BMD Exemestane N=29 Tamoxifen 1 N=38 Exemestane N=59 Placebo 1 N=65 Lumbar spine (%) -3.1 -0.2 -3.5 -2.4 Femoral neck (%) -4.2 -0.3 -4.6 -2.6 During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally… (نشرة إكسيميستان، التحذيرات والاحتياطات)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (نشرة إكسيميستان، التداخلات الدوائية)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (نشرة إكسيميستان، التحذيرات والاحتياطات)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (نشرة إكسيميستان، التحذيرات والاحتياطات)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (نشرة إكسيميستان، التحذيرات والاحتياطات)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (نشرة إكسيميستان، التحذيرات والاحتياطات)

Drugs That Induce CYP 3A4 Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. (نشرة إكسيميستان، التداخلات الدوائية)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (نشرة إكسيميستان، التحذيرات والاحتياطات)

• Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (نشرة إكسيميستان، التحذيرات والاحتياطات)

In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with EXEMESTANE and in 1.8% of patients treated with megestrol acetate. (نشرة إكسيميستان، التحذيرات والاحتياطات)